With the bill's drug-import provision made moot, the Senate voted overwhelmingly to require the FDA to monitor drugs after they have gone to market and drugmakers to reveal trial data. The 93-1 vote sent the measure to the House where similar legislation is pending. The Senate version also would order changes in drug labels and advertising as well as support the FDA's new powers through additional user fees.

Related Summaries